Skip to main navigation
Skip to search
Skip to main content
Ben-Gurion University Research Portal Home
Help & FAQ
Home
Profiles
Research output
Research units
Prizes
Press/Media
Student theses
Activities
Research Labs / Equipment
Datasets
Projects
Search by expertise, name or affiliation
CASE REPORT OF IRRITABLE BOWEL SYNDROME RESPONDING TO OMALIZUMAB
E. Magen, T. Chikovani
Barzilai University Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'CASE REPORT OF IRRITABLE BOWEL SYNDROME RESPONDING TO OMALIZUMAB'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Irritable Bowel Syndrome
100%
Omalizumab
100%
Therapeutic Potential
14%
Prospective Randomized Trial
14%
Older Women
14%
Chronic Abdominal Pain
14%
Common Disease
14%
Gastrointestinal Diseases
14%
Pharmacological Tools
14%
Chronic Spontaneous Urticaria
14%
Antihistamines
14%
Total Immunoglobulin E
14%
Recombinant DNA
14%
Current Therapies
14%
Humanized
14%
Multifactorial Etiology
14%
IgG1 Monoclonal Antibody
14%
Professional Healthcare
14%
Level of Frustration
14%
Altered Bowel Habits
14%
Medicine and Dentistry
Irritable Bowel Syndrome
100%
Omalizumab
100%
Health Care
14%
Disease
14%
Epileptic Absence
14%
Symptom
14%
Abdominal Pain
14%
Monoclonal Antibody
14%
Immunoglobulin E
14%
Chronic Urticaria
14%
Histamine Antagonist
14%
Recombinant DNA
14%
Immunoglobulin G1
14%
Defecation Habit
14%
Human Immunoglobulin
14%
Pharmacology, Toxicology and Pharmaceutical Science
Omalizumab
100%
Irritable Colon
100%
Recombinant DNA
14%
Disease
14%
Symptom
14%
Epileptic Absence
14%
Monoclonal Antibody
14%
Immunoglobulin E
14%
Abdominal Pain
14%
Chronic Urticaria
14%
Antihistaminic Agent
14%
Human Immunoglobulin
14%
Immunoglobulin G1
14%